Arrivo BioVentures

About Arrivo BioVentures

Arrivo BioVentures is a biopharmaceutical holding company for Sirtsei Pharmaceuticals, Inc. and Panafina Inc., focused on developing first-of-its-kind medicines for hard-to-treat diseases. Their mission is to target diseases at their source to achieve meaningful outcomes for patients, enabling longer, healthier lives.

Products & Services

SP-624 (Forvisirvat):A drug candidate developed by Sirtsei Pharmaceuticals for major depressive disorder, featuring a new mechanism of action.

RABI-767:A drug candidate developed by Panafina, Inc. for the treatment of patients predicted to advance to severe acute pancreatitis, also featuring a new mechanism of action.

Specialties

Development of first-of-its-kind medicines Targeting root causes of hard-to-treat diseases Major depressive disorder treatment Severe acute pancreatitis treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 45250000 MR: - FA: $45.25 million FAN: 45250000	D: 2023-11-29 FD: 2023-11-29	4 investors

Series B Latest

2023-11-29

$45.2M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Stephen E. Butts

Chief Executive Officer

J

John Hixon

Head of Corporate Development

K

Karen Adams

Chief Financial Officer

J

Joel Raskin

Chief Medical Officer

G

Greg Rigdon

Senior Vice President, Scientific Affairs

K

Kelly Abernathy

Vice President of Clinical Development

View 10 more team members with Pro

Unlock Full Team Directory

Recent News